The U.S. Food and Drug Administration has approved the first “digital pill,” designed to allow doctors to monitor whether patients with mental illnesses are taking it, Bloomberg reports. The sensor, created by Proteus Digital Health, is activated by stomach fluids. When used as part of the Abilify drug, designed to treat depression and schizophrenia, the sensor will transmit information to a smartphone app. Patients using the product must agree to allow physicians to see the data and choose whether the information will be shared with caregivers. Several organizations also plan on gathering anonymized, aggregated data from consenting patients. Despite these efforts, Omada Health Inc. Chief Privacy and Regulatory Officer Lucia Savage suggests patients and doctors ask questions regarding the sensor, data flows, and the servers where the data will be located. Editor's Note: Proteus Digital Health Co-Founder George Savage talked about the privacy concerns with ingestibles on an IAPP web conference.
If you want to comment on this post, you need to login.